Olivia Brayer

Stephen Brozak

Brandon Folkes

Serge Belanger

Steve Brozak

- **ARS Pharmaceuticals, Inc.** (Nasdaq: SPRY) has entered into a senior secured term loan facility of up to **$250 million** with affiliates of RA Capital Management and OMERS Life Sciences.  **[1285819_61e5153a201643db99af95773e9d1fd9_0]** 
- An initial **$100 million** has been borrowed to accelerate the commercial growth of **_neffy_**, its needle-free epinephrine nasal spray, and support marketing and medical affairs initiatives.  **[1285819_61e5153a201643db99af95773e9d1fd9_0]** 
- The funding is intended to strengthen the company's commercial strategy, generate real-world evidence for **_neffy_**'s effectiveness, and fund operations through expected cash-flow breakeven without shareholder dilution.  **[1285819_61e5153a201643db99af95773e9d1fd9_0]** **[1285819_61e5153a201643db99af95773e9d1fd9_1]** **[1285819_61e5153a201643db99af95773e9d1fd9_2]** 
- The loan features an interest rate of SOFR plus 5.5% (subject to a 3.0% SOFR floor) and interest-only payments until its maturity in **September 2030**.  **[1285819_61e5153a201643db99af95773e9d1fd9_1]**

OMEROS (OMER)